ALPS Medical Breakthroughs ETF
SBIO

$38.87

2.44%

Market Cap: $119M

0

Funds holding %

of 6,710 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

20% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 5

3% more funds holding

Funds holding: 37 [Q1] → 38 (+1) [Q2]

1.55% less ownership

Funds ownership: 47.97% [Q1] → 46.42% (-1.55%) [Q2]

13% less capital invested

Capital invested by funds: $55.3M [Q1] → $47.8M (-$7.46M) [Q2]

46% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 13

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for SBIO.

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about SBIO published over the past 30 days

Biotech Stocks Are Perking Up. This ETF Is Responding

In a somewhat quiet fashion, long-lagging biotech stocks and exchange traded funds are perking up. The ALPS Medical Breakthroughs ETF (SBIO) is part of that group.

Biotech Stocks Are Perking Up. This ETF Is Responding

VettaFi Is Finalist for 4 ETF Awards

The TMX VettaFi business segment is less than a year old, but it is already getting recognized for the breadth of its capabilities. Last week, we were named a finalist by ETF Express in four award categories.

VettaFi Is Finalist for 4 ETF Awards

Biotech ETF SBIO Rides Strong Momentum into Rate Cuts

While many investors are on the lookout for ETF opportunities in rate cuts, one particular strategy is already standing out. The biotech ETF SBIO is riding some positive momentum thanks to some major changes in the space this year.

Biotech ETF SBIO Rides Strong Momentum into Rate Cuts

Positive Biotech M&A Activity in 1H Boosts Case for Biotech ETF SBIO

Following some notable uncertainty in recent years, M&A activity looks to be in recovery. In the first half of this year, biotech M&A activity saw some positive numbers, per a new J.P.

Positive Biotech M&A Activity in 1H Boosts Case for Biotech ETF SBIO

Zacks Investment Research

Small-Cap ETFs to Rally on Upbeat U.S. Q2 GDP Growth Data?

The US economy expanded at a faster-than-expected pace in the second quarter of 2024. Small-cap stocks generally lead the way higher on improving American economy.

Small-Cap ETFs to Rally on Upbeat U.S. Q2 GDP Growth Data?

Returns Spiking for This Rate-Sensitive ETF

On the lookout for an ETF that might respond particularly well to rate cuts? One rate-sensitive ETF to watch is seeing returns spike even before rate cuts arrive.

Returns Spiking for This Rate-Sensitive ETF

Zacks Investment Research

The Zacks Analyst Blog KBWR, QQQS, SVAL, EES and SBIO

KBWR, QQQS, SVAL, EES and SBIO are included in this Analyst Blog.

The Zacks Analyst Blog KBWR, QQQS, SVAL, EES and SBIO

Zacks Investment Research

5 Small-Cap ETFs at the Forefront of the Latest Rally

Small-cap stocks have staged a strong comeback buoyed by the Trump trade resurgence and the growing expectations of the Fed cutting rates in September.

5 Small-Cap ETFs at the Forefront of the Latest Rally

Patent Cliffs Could Spark Wave of Biotech M&A

There's long been talk of a new wave of biotech mergers and acquisitions activity coming to life. In modest amounts, there has been evidence of that playing out.

Patent Cliffs Could Spark Wave of Biotech M&A

Big Pharma Has the Firepower for Biotech Deal-Making

In the early innings of 2024, there was a flurry of consolidation in the biotech industry. It stoked hopes that this would finally be the year in which well-heeled blue-chip pharmaceutical companies would spend some of their cash on faster-growing biotech firms.

Big Pharma Has the Firepower for Biotech Deal-Making

See News Rankings